BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
      • Artificial intelligence
    • Coronavirus
    • Israel
    • IVDs on the rise
    • Radiopharmaceuticals
    • Rise of obesity
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, November 29, 2023
Home » Stock Winners and Losers For The Week
X
/images/Cortellis_Flagship_Logo_TM_RGB_Color.png

Upgrade your daily dose of biopharma and medtech news

Subscribe to BioWorld™ news services

See subscription options

Stock Winners and Losers For The Week

April 4, 2005
No Comments

Article reprints
BioWorld MedTech

    Popular Stories

    • Today's news in brief

      BioWorld
      BioWorld briefs for Nov. 29, 2023.

    • Today's news in brief

      BioWorld MedTech
      BioWorld MedTech briefs for November, 29 2023.
    • Joint pain

      Aurinia Therapeutics’ AUR-300 proven useful in systemic sclerosis

      BioWorld Science
      Aurinia Pharmaceuticals Inc. has investigated their CD206 ligand AUR-300 as a novel therapeutic agent for systemic sclerosis treatment.
    • Red blood cells, DNA

      Historic MHRA exa-cel win bagged, Crispr/Vertex await FDA nod

      BioWorld
      With a landmark U.K. approval in hand for Casgevy (exagamglogene autotemcel [exa-cel]) to treat sickle cell disease and transfusion-dependent beta thalassemia,...
    • Breast cancer illustration

      Astrazeneca’s AKT inhibitor is approved in breast cancer

      BioWorld
      Along with Enhertu, Astrazeneca plc now has another breast cancer treatment in its portfolio and it may also become a blockbuster. Truqap (capivasertib), combined...
    black cortellis ad

    BioWorld Premium

    Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

    Subscribe
    • BioWorld
      • Today's news
      • Analysis and data insight
      • Clinical
      • Data Snapshots
      • Deals and M&A
      • Financings
      • Newco news
      • Opinion
      • Regulatory
      • Science
    • BioWorld MedTech
      • Today's news
      • Clinical
      • Data Snapshots
      • Deals and M&A
      • Financings
      • Newco news
      • Opinion
      • Regulatory
      • Science
    • BioWorld Asia
      • Today's news
      • Analysis and data insight
      • Australia
      • China
      • Clinical
      • Deals and M&A
      • Financings
      • Newco news
      • Regulatory
      • Science
    • BioWorld Science
      • Today's news
      • Biomarkers
      • Cancer
      • Conferences
      • Endocrine/Metabolic
      • Immune
      • Infection
      • Neurology/Psychiatric
      • Patents
    • More
      • About
      • Advertise with BioWorld
      • Archives
      • Article reprints and permissions
      • Contact us
      • Cookie policy
      • Copyright notice
      • Data methodology
      • Podcasts
      • Privacy policy
      • Share your news with BioWorld
      • Staff
      • Terms of use
      • Topic alerts
    Follow Us

    Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing